The global dendritic cell cancer vaccine market accounted for USD 0.681 billion in 2023 and is expected to reach USD 2.42 billion by 2034 with a CAGR of 12.21% during the forecast period 2024-2034. The rising incidence of cancer, improvements in immunotherapy, a focus on personalized medicine, a supportive regulatory environment, and a rise in alliances and collaborations will propel market expansion.
Vaccines against dendritic cell cancer are frequently tailored therapies, based on the immune system and tumor antigens of the individual patient. The need for dendritic cell vaccines is increasing because of the growing trend toward personalized medicine, which is being driven by advances in genomics, molecular biology, and diagnostics. These vaccines provide a customized approach to cancer treatment. For instance, Dendreon announced in November 2022 the start of a Phase 2 clinical trial to assess the safety and effectiveness of its cancer vaccine derived from dendritic cells when used in conjunction with other immunotherapies to treat metastatic prostate cancer.
By product, the Sipuleucel-T (Provenge) segment accounted for the highest revenue-grossing segment in the global dendritic cell cancer vaccine market in 2023 owing to the established efficacy and approval for advanced prostate cancer treatment, along with its pioneering status as the first FDA-approved dendritic cell cancer vaccine. For instance, Northwest Biotherapeutics stated in January 2023 that a Phase 3 clinical study for DCVax®-L, a vaccine based on dendritic cells, will begin in order to treat glioblastoma multiforme (GBM), a kind of brain cancer. Additionally, the CreaVax segment is predicted to grow at the fastest CAGR during the forecast period owing to the promising results from ongoing clinical trials, its innovative technology platform, and its potential for targeting a wide range of cancer types.
By end-user, the adult segment accounted for the highest revenue-grossing segment in the global dendritic cell cancer vaccine market in 2023 owing to the increasing prevalence of cancer in the adult population and the higher adoption of immunotherapies among this demographic group. For instance, Argos Therapeutics reported encouraging interim findings in September 2022 from its current Phase 2 trial assessing the safety and effectiveness of its dendritic cell-based immunotherapy for the treatment of renal cell carcinoma. Additionally, the pediatric segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing awareness of childhood cancers, advancements in pediatric oncology research, and the development of targeted immunotherapies tailored for pediatric patients.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of well-established healthcare infrastructure, extensive research and development activities, high adoption of novel cancer therapies, and supportive regulatory frameworks in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of cancer, improving healthcare infrastructure, rising awareness about advanced treatment options, and growing investments in oncology research and development in the region. For instance, ImmunoCellular Therapeutics reported in November 2022 that positive interim data from its Phase 1 trial assessing its dendritic cell-based immunotherapy for the treatment of glioblastoma multiforme (GBM) had been presented.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Vaccines against dendritic cell cancer are frequently tailored therapies, based on the immune system and tumor antigens of the individual patient. The need for dendritic cell vaccines is increasing because of the growing trend toward personalized medicine, which is being driven by advances in genomics, molecular biology, and diagnostics. These vaccines provide a customized approach to cancer treatment. For instance, Dendreon announced in November 2022 the start of a Phase 2 clinical trial to assess the safety and effectiveness of its cancer vaccine derived from dendritic cells when used in conjunction with other immunotherapies to treat metastatic prostate cancer.
By product, the Sipuleucel-T (Provenge) segment accounted for the highest revenue-grossing segment in the global dendritic cell cancer vaccine market in 2023 owing to the established efficacy and approval for advanced prostate cancer treatment, along with its pioneering status as the first FDA-approved dendritic cell cancer vaccine. For instance, Northwest Biotherapeutics stated in January 2023 that a Phase 3 clinical study for DCVax®-L, a vaccine based on dendritic cells, will begin in order to treat glioblastoma multiforme (GBM), a kind of brain cancer. Additionally, the CreaVax segment is predicted to grow at the fastest CAGR during the forecast period owing to the promising results from ongoing clinical trials, its innovative technology platform, and its potential for targeting a wide range of cancer types.
By end-user, the adult segment accounted for the highest revenue-grossing segment in the global dendritic cell cancer vaccine market in 2023 owing to the increasing prevalence of cancer in the adult population and the higher adoption of immunotherapies among this demographic group. For instance, Argos Therapeutics reported encouraging interim findings in September 2022 from its current Phase 2 trial assessing the safety and effectiveness of its dendritic cell-based immunotherapy for the treatment of renal cell carcinoma. Additionally, the pediatric segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing awareness of childhood cancers, advancements in pediatric oncology research, and the development of targeted immunotherapies tailored for pediatric patients.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of well-established healthcare infrastructure, extensive research and development activities, high adoption of novel cancer therapies, and supportive regulatory frameworks in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of cancer, improving healthcare infrastructure, rising awareness about advanced treatment options, and growing investments in oncology research and development in the region. For instance, ImmunoCellular Therapeutics reported in November 2022 that positive interim data from its Phase 1 trial assessing its dendritic cell-based immunotherapy for the treatment of glioblastoma multiforme (GBM) had been presented.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Dendritic Cell Cancer Vaccine Market Report 2023 - 2034
Dendritic Cell Cancer Vaccine Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- CreaVax
- Sipuleucel-T (Provenge)
- Other
Dendritic Cell Cancer Vaccine Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Pediatrics
- Adults
Dendritic Cell Cancer Vaccine Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Dendritic Cell Cancer Vaccine Market: Product Estimates & Trend Analysis
8. Dendritic Cell Cancer Vaccine Market: End-User Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Dendritic Cell Cancer Vaccine Market
11. Europe Global Dendritic Cell Cancer Vaccine Market
12. Asia Pacific Global Dendritic Cell Cancer Vaccine Market
13. Latin America Global Dendritic Cell Cancer Vaccine Market
14. MEA Global Dendritic Cell Cancer Vaccine Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Dendreon Pharmaceuticals LLC
- Northwest Biotherapeutics Inc.
- Argos Therapeutics Inc.
- ImmunoCellular Therapeutics Ltd.
- Immatics Biotechnologies GmbH
- Bellicum Pharmaceuticals Inc.
- Tella Inc.
- GlaxoSmithKline plc
- Batavia Biosciences B.V.
- Elios Therapeutics LLC
- SELLAS Life Sciences Group Inc.
- Medigene AG
- DCPrime BV
- NexImmune Inc.
- Kite Pharma Inc.
